VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity
•We discuss the role of VISTA as a negative checkpoint directing both innate and adaptive immunity.•VISTA is broadly expressed on myeloid and T cells, and increases with tumor progression.•VISTA is a unique target with both antagonistic and agonistic antibodies available.•VISTA presents an attractiv...
Gespeichert in:
| Veröffentlicht in: | Seminars in immunology 2019-04, Vol.42, p.101308-101308, Article 101308 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101308 |
|---|---|
| container_issue | |
| container_start_page | 101308 |
| container_title | Seminars in immunology |
| container_volume | 42 |
| creator | ElTanbouly, Mohamed A. Croteau, Walburga Noelle, Randolph J. Lines, J. Louise |
| description | •We discuss the role of VISTA as a negative checkpoint directing both innate and adaptive immunity.•VISTA is broadly expressed on myeloid and T cells, and increases with tumor progression.•VISTA is a unique target with both antagonistic and agonistic antibodies available.•VISTA presents an attractive target for cancer immunotherapy with preclinical studies showing promising outcomes of anti-VISTA in multiple models.
V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landscape for influencing the outcome of cancer and inflammatory diseases. |
| doi_str_mv | 10.1016/j.smim.2019.101308 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7233310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1044532319300338</els_id><sourcerecordid>2305054307</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-c2f22cc5061a9801b930194cf9f11828742d81cfd01a133a3b1efea6ec900dae3</originalsourceid><addsrcrecordid>eNp9UU1r3DAQFaWlSdP-gR6Kj714M6OxvXYphSX0IxBIoGmvQiuPN1psaStpFza_vjZOQ3LpaYaZ9958PCHeIywQsDrfLuJgh4UEbKYCQf1CnCI0VU4V1i-nvCjykiSdiDcxbgGAihpfixPCCoqS8FTc_L78ebv6lK0y5w_cZ3YY9s6nOw56d8ySDhtOWefD2A6D7u29dZvMOqcTZ9q1mW71LtkDz0Sbjm_Fq073kd89xDPx69vX24sf-dX198uL1VVuSlmm3MhOSmNKqFA3NeC6ofGMwnRNh1jLelnItkbTtYAaiTStkTvWFZsGoNVMZ-LLrLvbrwduDbsUdK92wQ46HJXXVj3vOHunNv6glpKIEEaBjw8Cwf_Zc0xqsNFw32vHfh-VJCihLAiWI1TOUBN8jIG7xzEIarJCbdVkhZqsULMVI-nD0wUfKf9-PwI-zwAe33SwHFQ0lp3h1gY2SbXe_k__LwMrm58</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2305054307</pqid></control><display><type>article</type><title>VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>ElTanbouly, Mohamed A. ; Croteau, Walburga ; Noelle, Randolph J. ; Lines, J. Louise</creator><creatorcontrib>ElTanbouly, Mohamed A. ; Croteau, Walburga ; Noelle, Randolph J. ; Lines, J. Louise</creatorcontrib><description>•We discuss the role of VISTA as a negative checkpoint directing both innate and adaptive immunity.•VISTA is broadly expressed on myeloid and T cells, and increases with tumor progression.•VISTA is a unique target with both antagonistic and agonistic antibodies available.•VISTA presents an attractive target for cancer immunotherapy with preclinical studies showing promising outcomes of anti-VISTA in multiple models.
V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landscape for influencing the outcome of cancer and inflammatory diseases.</description><identifier>ISSN: 1044-5323</identifier><identifier>EISSN: 1096-3618</identifier><identifier>DOI: 10.1016/j.smim.2019.101308</identifier><identifier>PMID: 31604531</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adaptive Immunity ; Agonist ; Animals ; Antagonist ; Autoimmunity ; B7 Antigens - immunology ; Cancer immunotherapy ; Humans ; Immune checkpoint ; Immunity, Innate ; Immunotherapy ; Neoplasms - immunology ; Neoplasms - therapy ; VISTA</subject><ispartof>Seminars in immunology, 2019-04, Vol.42, p.101308-101308, Article 101308</ispartof><rights>2019</rights><rights>Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-c2f22cc5061a9801b930194cf9f11828742d81cfd01a133a3b1efea6ec900dae3</citedby><cites>FETCH-LOGICAL-c525t-c2f22cc5061a9801b930194cf9f11828742d81cfd01a133a3b1efea6ec900dae3</cites><orcidid>0000-0002-3766-8376 ; 0000-0002-2222-2136</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.smim.2019.101308$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31604531$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ElTanbouly, Mohamed A.</creatorcontrib><creatorcontrib>Croteau, Walburga</creatorcontrib><creatorcontrib>Noelle, Randolph J.</creatorcontrib><creatorcontrib>Lines, J. Louise</creatorcontrib><title>VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity</title><title>Seminars in immunology</title><addtitle>Semin Immunol</addtitle><description>•We discuss the role of VISTA as a negative checkpoint directing both innate and adaptive immunity.•VISTA is broadly expressed on myeloid and T cells, and increases with tumor progression.•VISTA is a unique target with both antagonistic and agonistic antibodies available.•VISTA presents an attractive target for cancer immunotherapy with preclinical studies showing promising outcomes of anti-VISTA in multiple models.
V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landscape for influencing the outcome of cancer and inflammatory diseases.</description><subject>Adaptive Immunity</subject><subject>Agonist</subject><subject>Animals</subject><subject>Antagonist</subject><subject>Autoimmunity</subject><subject>B7 Antigens - immunology</subject><subject>Cancer immunotherapy</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immunity, Innate</subject><subject>Immunotherapy</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>VISTA</subject><issn>1044-5323</issn><issn>1096-3618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1r3DAQFaWlSdP-gR6Kj714M6OxvXYphSX0IxBIoGmvQiuPN1psaStpFza_vjZOQ3LpaYaZ9958PCHeIywQsDrfLuJgh4UEbKYCQf1CnCI0VU4V1i-nvCjykiSdiDcxbgGAihpfixPCCoqS8FTc_L78ebv6lK0y5w_cZ3YY9s6nOw56d8ySDhtOWefD2A6D7u29dZvMOqcTZ9q1mW71LtkDz0Sbjm_Fq073kd89xDPx69vX24sf-dX198uL1VVuSlmm3MhOSmNKqFA3NeC6ofGMwnRNh1jLelnItkbTtYAaiTStkTvWFZsGoNVMZ-LLrLvbrwduDbsUdK92wQ46HJXXVj3vOHunNv6glpKIEEaBjw8Cwf_Zc0xqsNFw32vHfh-VJCihLAiWI1TOUBN8jIG7xzEIarJCbdVkhZqsULMVI-nD0wUfKf9-PwI-zwAe33SwHFQ0lp3h1gY2SbXe_k__LwMrm58</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>ElTanbouly, Mohamed A.</creator><creator>Croteau, Walburga</creator><creator>Noelle, Randolph J.</creator><creator>Lines, J. Louise</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3766-8376</orcidid><orcidid>https://orcid.org/0000-0002-2222-2136</orcidid></search><sort><creationdate>20190401</creationdate><title>VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity</title><author>ElTanbouly, Mohamed A. ; Croteau, Walburga ; Noelle, Randolph J. ; Lines, J. Louise</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-c2f22cc5061a9801b930194cf9f11828742d81cfd01a133a3b1efea6ec900dae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adaptive Immunity</topic><topic>Agonist</topic><topic>Animals</topic><topic>Antagonist</topic><topic>Autoimmunity</topic><topic>B7 Antigens - immunology</topic><topic>Cancer immunotherapy</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immunity, Innate</topic><topic>Immunotherapy</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>VISTA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ElTanbouly, Mohamed A.</creatorcontrib><creatorcontrib>Croteau, Walburga</creatorcontrib><creatorcontrib>Noelle, Randolph J.</creatorcontrib><creatorcontrib>Lines, J. Louise</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Seminars in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ElTanbouly, Mohamed A.</au><au>Croteau, Walburga</au><au>Noelle, Randolph J.</au><au>Lines, J. Louise</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity</atitle><jtitle>Seminars in immunology</jtitle><addtitle>Semin Immunol</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>42</volume><spage>101308</spage><epage>101308</epage><pages>101308-101308</pages><artnum>101308</artnum><issn>1044-5323</issn><eissn>1096-3618</eissn><abstract>•We discuss the role of VISTA as a negative checkpoint directing both innate and adaptive immunity.•VISTA is broadly expressed on myeloid and T cells, and increases with tumor progression.•VISTA is a unique target with both antagonistic and agonistic antibodies available.•VISTA presents an attractive target for cancer immunotherapy with preclinical studies showing promising outcomes of anti-VISTA in multiple models.
V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landscape for influencing the outcome of cancer and inflammatory diseases.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31604531</pmid><doi>10.1016/j.smim.2019.101308</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3766-8376</orcidid><orcidid>https://orcid.org/0000-0002-2222-2136</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-5323 |
| ispartof | Seminars in immunology, 2019-04, Vol.42, p.101308-101308, Article 101308 |
| issn | 1044-5323 1096-3618 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7233310 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adaptive Immunity Agonist Animals Antagonist Autoimmunity B7 Antigens - immunology Cancer immunotherapy Humans Immune checkpoint Immunity, Innate Immunotherapy Neoplasms - immunology Neoplasms - therapy VISTA |
| title | VISTA: A novel immunotherapy target for normalizing innate and adaptive immunity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T22%3A33%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VISTA:%20A%20novel%20immunotherapy%20target%20for%20normalizing%20innate%20and%20adaptive%20immunity&rft.jtitle=Seminars%20in%20immunology&rft.au=ElTanbouly,%20Mohamed%20A.&rft.date=2019-04-01&rft.volume=42&rft.spage=101308&rft.epage=101308&rft.pages=101308-101308&rft.artnum=101308&rft.issn=1044-5323&rft.eissn=1096-3618&rft_id=info:doi/10.1016/j.smim.2019.101308&rft_dat=%3Cproquest_pubme%3E2305054307%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2305054307&rft_id=info:pmid/31604531&rft_els_id=S1044532319300338&rfr_iscdi=true |